Kerrisdale’s Short Bets Go the Wrong Way

Activist manager Sahm Adrangi’s firm has had a tough year, in part due to a big short bet against Dish Network.

Photo credit: Bloomberg

By Michelle Celarier

When Zafgen, a small Boston biotechnology company, said in late July that it was suspending production of a weight-loss drug that has drawn scrutiny from the Food and Drug Administration for life-threatening side effects, no one could have been happier than Sahm Adrangi, a cocky 35-year-old hedge fund manager who’s in the red...

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.